Merck’s (MRK) supplemental applications seeking approval for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX for the adjuvant treatment of patients with clear cell renal cell carcinoma (RCC) following nephrectomy are under priority review by the FDA, with a decision expected on June 19, 2026.KEYTRUDA is approved for the adjuvant treatment of certain patients with RCC in the U.S., Canada, the European Union (EU), Japan and other countries worldwide.WELIREG, also from the stable of Merck, is approved in over 45 countries, including the U.S., Canada, the EU, and Japan, for the treatment of adult patients with advanced RCC following a PD-1/PD-L1 inhibitor and 1-2 VEGF-TKIs.MRK closed Tuesday’s (June 2, 2026) trading at $115.65, up 0.42%.